SCHEDULE: Acorn Entities Report Stake in enGene Therapeutics

Acorn Bioventures, L.P., Acorn Capital Advisors GP, LLC, Acorn Bioventures 2, L.P., Acorn Capital Advisors GP 2, LLC, and Anders Hove have collectively reported beneficial ownership of 5.0% of enGene Therapeutics Inc. common shares.

Summary

• Acorn Bioventures, L.P. and Acorn Bioventures 2, L.P., both Delaware limited partnerships, along with their respective general partners Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC, have filed a Schedule 13G.
• Anders Hove, a U.S. citizen and Manager of the general partners, is also included in the filing.
• The filing indicates shared voting and dispositive power over a total of 3,357,282 shares of enGene Therapeutics Inc. common stock.
• This represents 5.0% of the class of securities outstanding as of June 9, 2026.
• The total number of outstanding shares used for this calculation is 66,989,466, as reported in enGene Therapeutics' Form 10-Q for the period ended March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not provide new operational or financial information about the company.

Positives

• Significant reporting of beneficial ownership by Acorn entities and Anders Hove, indicating substantial investment interest.
• Clear disclosure of share percentages and outstanding shares, providing transparency to the market.

Risks

• The filing does not contain information on specific risks related to the company's operations or financial health, as it is a Schedule 13G disclosure of beneficial ownership.

Future Outlook

This filing is a Schedule 13G, which reports beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for significant institutional investors and do not inherently signal a change in company strategy or performance, but rather a reporting of ownership levels.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes, which can influence market perception.
• Management: Awareness of substantial beneficial ownership by Acorn entities and Anders Hove.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, enGene Therapeutics, Acorn Bioventures, Acorn Capital Advisors, Common Shares, SEC Filing, Investment